TITLE

Response to infliximab in fistulizing Crohn's disease is independent of baseline number of draining fistulas

AUTHOR(S)
Sands, Bruce E; Thorne, Nicole A; Marsters, Paul A; Blank, Marion A
PUB. DATE
September 2003
SOURCE
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS239
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
An abstract of the article concerning infliximab in fistulizing Crohn's disease is presented.
ACCESSION #
66954790

 

Related Articles

  • Safety and steroid-sparing experience using infliximab for Crohn’s disease at a pediatric inflammatory bowel disease center. Stephens, Michael C.; Shepanski, Melissa A.; Mamula, Petar; Markowitz, Jonathan E.; Brown, Kurt A.; Baldassano, Robert N. // American Journal of Gastroenterology;Jan2003, Vol. 98 Issue 1, p104 

    : ObjectivesThe published experience using infliximab (Remicade, Centocor, Malvern, PA) for the treatment of pediatric Crohn’s disease is limited but suggests utility in the treatment of refractory disease. Experience using infliximab at a large pediatric center is reviewed.: MethodsA...

  • Immunomodulators and “on demand” therapy with infliximab in Crohn’s disease: clinical experience with 400 infusions. Kinney, Timothy; Rawlins, Matthew; Kozarek, Richard; France, Renée; Patterson, David // American Journal of Gastroenterology;Mar2003, Vol. 98 Issue 3, p608 

    : ObjectivesInfliximab has been proven effective for treatment of active Crohn’s and fistulizing Crohn’s disease. We reviewed our experience with infliximab in patients with Crohn’s disease to determine if its combination with immunomodulators leads to better response and...

  • Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease Van Assche, Gert; Vanbeckevoort, Dirk; Bielen, Didier; Coremans, Georges; Aerden, Isolde; Noman, Maya; D’Hoore, Andre; Penninckx, Freddy; Marchal, Guy; Cornillie, Freddy; Rutgeerts, Paul // American Journal of Gastroenterology;Feb2003, Vol. 98 Issue 2, p332 

    : ObjectivesAlthough the clinical efficacy of infliximab as measured by closure of fistulas in Crohn’s disease has been demonstrated, its influence on the inflammatory changes in the fistula tracks is less clear. The aim of the present study was to assess the behavior of perianal fistulas...

  • Management of Crohn's disease of the ileoanal pouch with infliximab Colombel, Jean-Frederic; Ricart, Elena; Loftus Jr., Edward V.; Tremaine, William J.; Young-Fadok, Tonia; Dozois, Eric J.; Wolff, Bruce G.; Devine, Richard; Pemberton, John H.; Sandborn, William J. // American Journal of Gastroenterology;Oct2003, Vol. 98 Issue 10, p2239 

    : ObjectivesThe occurrence of Crohn''s disease (CD) in a patient with an ileal-pouch anstomosis (IPAA) often results in severe morbidity and significant chance of reservoir loss. We report our experience of the use of infliximab in these patients.: MethodsMedical records of 26 patients with an...

  • Infliximab/mercaptopurine.  // Reactions Weekly;6/25/2011, Issue 1357, p20 

    The article describes the case of a 19-year-old woman with Crohn's disease who developed melanocytic lesions after starting treatment with mercaptopurine and infliximab.

  • AZATHIOPRINE AND SMOKING STATUS IN CROHN'S DISEASE PREDICT RESPONSE TO INFLIXIMAB. Arnott, I.D.R.; Satsangi, J. // Gut;Apr2003 Supplement 1, Vol. 52, pA13 

    Introduction: Up to 75% of patients given infliximab for Crohn's disease (CD) will respond. A number of clinical parameters that may predict response have been proposed but none has been reproduced in an independent cohort. We aimed to identify clinical and laboratory markers of response in...

  • Infliximab.  // Reactions Weekly;10/2/2010, Issue 1321, p21 

    The article describes the case of a man who developed multifocal motor neuropathy with conduction block (MMNCB) following treatment with infliximab for Crohn's disease.

  • Infliximab.  // Reactions Weekly;5/26/2012, Issue 1403, p18 

    The article describes the case of an adult woman who developed paradoxical exacerbation of Crohn's disease (CD) after receiving infliximab.

  • Infliximab.  // Reactions Weekly;03/01/2013, Issue 1441, p21 

    The article presents a case study of a 29-year-old woman who developed acute cytolytic hepatitis while receiving infliximab (Remicade) for vulvar Crohn's disease.

  • Infliximab.  // Reactions Weekly;10/16/2010, Issue 1323, p25 

    The article describes the cases of two women who developed Lewis-Summer syndrome (LSS) while receiving treatment with infliximab for Crohn's disease (CD).

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics